Please be patient! It may take up to ONE minute to load all the Engines.
Problems? Please contact our support.
Chronic myelogenous leukemia (CML)
Alternative namesChronic granulocytic leukemia
DefinitionChronic myelogenous leukemia is a malignant cancer of the bone marrow that causes rapid growth of the blood forming cells (known as myeloid precursors) in the bone marrow, peripheral blood, and body tissues.
Causes, incidence, and risk factors
The disease occurs in middle-aged people and children and is associated with a chromosome abnormality called the Philadelphia chromosome . Chronic myelogenous leukemia is characterized by a chronic phase that can last for months or years. The disease may have few or no symptoms during the chronic phase. Eventually, patients progress from the chronic phase to a more dangerous "accerated phase," during which the leukemia cells grow more quickly.
Acceleration of the disease may be associated with fever (without infection), bone pain and an enlarged spleen . Within 5 years, in most people, the disease then progresses to a "blast crisis," when there is a very high count of immature white blood cells (leukemia cells). The blast phase of the leukemia is very difficult to treat. Bleeding and infection may occur due to bone marrow failure.
Known risk factors to develop CML are exposure to ionizing radiation and benzene.
Signs and testsA physical examination often reveals an enlarged spleen .
Treatment is aimed at reducing the growth of the leukemic cells in the bone marrow and may bring about a remission (when no leukemia can be found) with good control of the symptoms of the disease.
The FDA recently approved a new drug for CML called imatineb (Gleevec), which is particularly effective when the disease has not responded to standard treatment (bone marrow transplant). This drug works directly on the leukemic cells to slow their growth. A bone marrow transplant preceded by high-dose chemotherapy and radiation therapy remains the standard treatment, however, although not all people with CML are suitable candidates for transplantation or have a suitable donor.
It is not known at the present time which patients should receive a bone marrow transplant as the first treatment and who should receive Gleevec. Participation in a medical study ("clinical trial") comparing these treatments may be appropriate. Since treatment recommedations for CML are changing quickly with new research findings, you should discuss in detail with your oncologist the advantages and disadvantages of each option.
Support GroupsThe stress of illness can often be helped by joining a support group where members share common experiences and problems. For this condition, see cancer - support group and leukemia - support group.
Without curative treatment, the disease is always fatal. On average, the survival is 3 to 4 years. Over half of those who receive a bone marrow transplant have long-term disease-free survival. The long-term survival after Gleevec alone is not known.
Blast crisis can lead to complications of CML, including infection, bleeding, fatigue, unexplained fever, and kidney problems. Chemotherapy can have serious side effects, depending on the drugs used.
Calling your health care providerCall your health care provider if you have symptoms suggestive of CML or have been diagnosed with CML and develop a fever higher than 100 degrees Fahrenheit, chills, sore throat, or cough.
Avoid radiation and benzene if possible.
Update Date: 8/8/2002Scott Howard, M.D., M.S., Department of Pediatric Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, TN. Review provided by VeriMed Healthcare Network.
Last updated: Tue, 06 Jan 2009 00:20:03 GMT